StreetInsider.com News Articles

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924046.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924046.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924046.html

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details

The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link:

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).

Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase